13,298 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Bought by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,298 shares of the biotechnology company's stock, valued at approximately $264,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics in the 4th quarter valued at about $35,000. Vision Financial Markets LLC purchased a new position in shares of ADMA Biologics during the fourth quarter worth about $51,000. AlphaQuest LLC acquired a new position in shares of ADMA Biologics in the fourth quarter valued at approximately $84,000. GF Fund Management CO. LTD. acquired a new stake in ADMA Biologics in the fourth quarter valued at about $85,000. Finally, CIBC Private Wealth Group LLC boosted its stake in shares of ADMA Biologics by 137.1% in the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after buying an additional 2,954 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on ADMA shares. Raymond James raised their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $24.25.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock traded down $0.27 during midday trading on Thursday, hitting $21.60. 3,627,666 shares of the company were exchanged, compared to its average volume of 3,670,358. The firm has a 50 day simple moving average of $20.81 and a 200-day simple moving average of $18.88. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 52 week low of $10.21 and a 52 week high of $25.67. The firm has a market cap of $5.16 billion, a P/E ratio of 77.14 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. During the same period in the previous year, the business posted $0.08 earnings per share. ADMA Biologics's revenue was up 40.2% compared to the same quarter last year. Research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Lawrence P. Guiheen sold 7,779 shares of ADMA Biologics stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total transaction of $158,069.28. Following the transaction, the director now owns 114,830 shares in the company, valued at approximately $2,333,345.60. The trade was a 6.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director now directly owns 478,194 shares of the company's stock, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,000 shares of company stock valued at $814,936. Company insiders own 3.50% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.